Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 11/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 8/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CRHBP | P24387 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.34 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.34 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18921688 | 1.00 | CNR1 (0.36) | CNR1S1PR1CNR2ALDH1A1TSHR | |
| SCHEMBL28725725 | 1.00 | CNR1 (0.36) | CNR1S1PR1CNR2ALDH1A1TSHR | |
| SCHEMBL21507538 | 0.86 | HSD11B1 (0.37) | CNR1S1PR1CNR2ALDH1A1KCNA5 | |
| SCHEMBL21507537 | 0.85 | SMN1; SMN2 (0.35) | CNR1S1PR1CNR2ALDH1A1TSHR | |
| SCHEMBL11891925 | 0.82 | CNR1 (0.38) | CNR1S1PR1CNR2ALDH1A1 | |
| SCHEMBL11025676 | 0.82 | CNR1 (0.38) | CNR1S1PR1CNR2ALDH1A1 | |
| SCHEMBL28934713 | 0.82 | CNR1 (0.38) | CNR1S1PR1CNR2ALDH1A1 | |
| SCHEMBL24682843 | 0.82 | CNR1 (0.38) | CNR1S1PR1CNR2ALDH1A1 | |
| SCHEMBL30439393 | 0.82 | CNR1 (0.38) | CNR1S1PR1CNR2ALDH1A1 | |
| SCHEMBL30268869 | 0.82 | CNR1 (0.38) | CNR1S1PR1CNR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220315569-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE | BRISTOL MYERS SQUIBB CO (US) | 2022-10-06 | — | — | US | disclosed |
| CN-108473466-B | Apelin receptor agonists and methods of use | 百时美施贵宝公司 | 2022-04-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315569-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE | APLNR, AP2B1, AP3B1 | CNR1 97/4885S1PR1 372/4885CNR2 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.